In summary, by interfering with the AR/FlnA complex, targeting several extracts, and inhibiting the activity of key factors, such as YAP1, CXCL12, and TGF-β, the pro-tumor function and ability to maintain the CAF tumor can be effectively impaired, providing a new approach for PCa treatment (Table 2). Here, CXCL12 is linked to neoplasm.